Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biotechnology company will post earnings of ($4.72) per share for the year. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

A number of other analysts also recently weighed in on ARWR. B. Riley restated a “buy” rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 6th. Citigroup reduced their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Finally, Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.71.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $16.22 on Wednesday. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The company has a market cap of $2.24 billion, a P/E ratio of -3.14 and a beta of 0.96. The firm’s fifty day moving average is $14.14 and its two-hundred day moving average is $17.29. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to the consensus estimate of $116.27 million. During the same quarter in the prior year, the firm posted ($1.02) earnings per share.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 40,322 shares of the company’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $10.07, for a total transaction of $406,042.54. Following the transaction, the chief executive officer now directly owns 4,022,055 shares in the company, valued at approximately $40,502,093.85. This represents a 0.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after buying an additional 2,774,933 shares during the period. Avoro Capital Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 25.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company’s stock valued at $208,889,000 after buying an additional 2,222,223 shares during the period. Norges Bank purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $38,622,000. Vanguard Group Inc. boosted its position in Arrowhead Pharmaceuticals by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after buying an additional 1,018,273 shares during the period. Finally, Farallon Capital Management LLC purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $11,821,000. 62.61% of the stock is currently owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.